000 04314nam a22003735i 4500
999 _c81165
_d81165
_x1
001 81165
003 ES-MaUEC
005 20230207040317.0
007 cr nn 008mamaa
008 141021s2015 xxu| s |||| 0|eng d
020 _a9781493910106
024 7 _a10.1007/978-1-4939-1010-6
_2doi
040 _dES-MaUEC
050 4 _aQP552.P4
_bL593 2015
100 1 _aLi, Yanyan
_0Local
_993432
245 1 0 _aLasso Peptides :
_bBacterial Strategies to Make and Maintain Bioactive Entangled Scaffolds
_cby Yanyan Li, Séverine Zirah, Sylvie Rebuffat
260 _aNew York
_bSpringer International Publishing
_c2015
300 _a1 recurso en línea (XIII, 103 p.)
_b22 ilustraciones, 9 ilustraciones en color
336 _aTexto (visual)
_btxt
_2rdacontent
337 _aelectrónico
_bc
_2rdamedia
338 _arecurso electrónico
_bcr
_2rdacarrier
490 0 _aSpringerBriefs in Microbiology
_x2191-5385
505 0 _aOverview on Lasso Peptide Research -- From the Producer Microorganisms to the Lasso Scaffold -- Biological Activities of Lasso Peptides and Structure-Activity Relationships -- Biosynthesis, Regulation and Export of Lasso Peptides -- Lasso Peptide Bioengineering and Bioprospecting.
520 _aLasso peptides form a growing family of fascinating ribosomally-synthesized and post-translationally modified peptides produced by bacteria. They contain 15 to 24 residues and share a unique interlocked topology that involves an N-terminal 7 to 9-residue macrolactam ring where the C-terminal tail is threaded and irreversibly trapped. The ring results from the condensation of the N-terminal amino group with a side-chain carboxylate of a glutamate at position 8 or 9, or an aspartate at position 7, 8 or 9. The trapping of the tail involves bulky amino acids located in the tail below and above the ring and/or disulfide bridges connecting the ring and the tail. Lasso peptides are subdivided into three subtypes depending on the absence (class II) or presence of one (class III) or two (class I) disulfide bridges. The lasso topology results in highly compact structures that give to lasso peptides an extraordinary stability towards both protease degradation and denaturing conditions. Lasso peptides are generally receptor antagonists, enzyme inhibitors and/or antibacterial or antiviral (anti-HIV) agents. The lasso scaffold and the associated biological activities shown by lasso peptides on different key targets make them promising molecules with high therapeutic potential. Their application in drug design has been exemplified by the development of an integrin antagonist based on a lasso peptide scaffold. The biosynthesis machinery of lasso peptides is therefore of high biotechnological interest, especially since such highly compact and stable structures have to date revealed inaccessible by peptide synthesis. Lasso peptides are produced from a linear precursor LasA, which undergoes a maturation process involving several steps, in particular cleavage of the leader peptide and cyclization. The post-translational modifications are ensured by a dedicated enzymatic machinery, which is composed of an ATP-dependent cysteine protease (LasB) and a lactam synthetase (LasC) that form an enzymatic complex called lasso synthetase. Microcin J25, produced by Escherichia coli AY25, is the archetype of lasso peptides and the most extensively studied. To date only around forty lasso peptides have been isolated, but genome mining approaches have revealed that they are widely distributed among Proteobacteria and Actinobacteria, particularly in Streptomyces, making available a rich resource of novel lasso peptides and enzyme machineries towards lasso topologies.
650 7 _2embne
_9146243
_aPéptidos
700 1 _aZirah, Séverine
_993433
_0Local
700 1 _aRebuffat, Sylvie
_993434
_0Local
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-1-4939-1010-6
_zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
907 _a.b12897553
_b10-10-17
_c18-01-16
942 _2lcc
_cLE
945 _aQP552.P4 L593 2015 EB
_g1
_ieBOOK
_j0
_lmae
_o-
_pEUR0.00
_q-
_r-
_sb
_t15
_u0
_v0
_w0
_x0
_y.i1156717x
_z06-04-17
988 _aEBSPRINGER
998 _am
_a_alco
_a_vill
_b - -
_cm
_dz
_e-
_feng
_gxxu
_h0